The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura, Hisayuki Shigematsu, Kunitoshi Tomii, Motoi Aoe, Kouichi Ichimura, Toshihide Tsuda, Masaaki Yano, Kazunori Tsukuda, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto, Hiroshi Date, Adi F. Gazdar, Nobuyoshi Shimizu

Research output: Contribution to journalArticle

440 Citations (Scopus)

Abstract

Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.

Original languageEnglish (US)
Pages (from-to)1167-1173
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number3
StatePublished - Feb 1 2005

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Exons
Smoke
Histology
erbB-1 Genes
Survival
Missense Mutation
Adenocarcinoma
Research Design
Multivariate Analysis
Smoking
gefitinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., ... Shimizu, N. (2005). The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clinical Cancer Research, 11(3), 1167-1173.

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. / Tokumo, Masaki; Toyooka, Shinichi; Kiura, Katsuyuki; Shigematsu, Hisayuki; Tomii, Kunitoshi; Aoe, Motoi; Ichimura, Kouichi; Tsuda, Toshihide; Yano, Masaaki; Tsukuda, Kazunori; Tabata, Masahiro; Ueoka, Hiroshi; Tanimoto, Mitsune; Date, Hiroshi; Gazdar, Adi F.; Shimizu, Nobuyoshi.

In: Clinical Cancer Research, Vol. 11, No. 3, 01.02.2005, p. 1167-1173.

Research output: Contribution to journalArticle

Tokumo, M, Toyooka, S, Kiura, K, Shigematsu, H, Tomii, K, Aoe, M, Ichimura, K, Tsuda, T, Yano, M, Tsukuda, K, Tabata, M, Ueoka, H, Tanimoto, M, Date, H, Gazdar, AF & Shimizu, N 2005, 'The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers', Clinical Cancer Research, vol. 11, no. 3, pp. 1167-1173.
Tokumo, Masaki ; Toyooka, Shinichi ; Kiura, Katsuyuki ; Shigematsu, Hisayuki ; Tomii, Kunitoshi ; Aoe, Motoi ; Ichimura, Kouichi ; Tsuda, Toshihide ; Yano, Masaaki ; Tsukuda, Kazunori ; Tabata, Masahiro ; Ueoka, Hiroshi ; Tanimoto, Mitsune ; Date, Hiroshi ; Gazdar, Adi F. ; Shimizu, Nobuyoshi. / The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 3. pp. 1167-1173.
@article{0a61c3cd7a8945de9e8eed464ea01b11,
title = "The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers",
abstract = "Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32{\%}) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.",
author = "Masaki Tokumo and Shinichi Toyooka and Katsuyuki Kiura and Hisayuki Shigematsu and Kunitoshi Tomii and Motoi Aoe and Kouichi Ichimura and Toshihide Tsuda and Masaaki Yano and Kazunori Tsukuda and Masahiro Tabata and Hiroshi Ueoka and Mitsune Tanimoto and Hiroshi Date and Gazdar, {Adi F.} and Nobuyoshi Shimizu",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "11",
pages = "1167--1173",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers

AU - Tokumo, Masaki

AU - Toyooka, Shinichi

AU - Kiura, Katsuyuki

AU - Shigematsu, Hisayuki

AU - Tomii, Kunitoshi

AU - Aoe, Motoi

AU - Ichimura, Kouichi

AU - Tsuda, Toshihide

AU - Yano, Masaaki

AU - Tsukuda, Kazunori

AU - Tabata, Masahiro

AU - Ueoka, Hiroshi

AU - Tanimoto, Mitsune

AU - Date, Hiroshi

AU - Gazdar, Adi F.

AU - Shimizu, Nobuyoshi

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.

AB - Purpose: Recent studies reported that clinical responsiveness to gefitinib was associated with somatic mutation of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers (NSCLC). Here, we investigated the relationship between EGFR mutation and clinicopathologic features. Experimental Design: EGFR mutational status of 120 NSCLCs was determined mainly in EGFR exons 18 to 21 by direct sequence and correlated with clinicopathologic parameters. Results: EGFR mutations were present in 38 cases (32%) and the majority of mutations were in-frame deletions of exon 19 (19 cases) and a missense mutation in exon 21 (18 cases). EGFR mutations were frequently associated with adenocarcinoma (P < 0.0001), never smoker (P < 0.0001), and female gender (P = 0.0001). Of interest, increasing smoke exposure was inversely related to the rate of EGFR mutation (P < 0.0001). Multivariate analysis showed that smoking and histology were independent variables. Furthermore, gender difference was observed for the mutational location (P = 0.01) dominance of exon 19 for males and exon 21 for females. Twenty-one cases were treated with gefitinib and found that EGFR mutation was significantly related to gefitinib responsiveness (P = 0.002). In addition, median survival times of patients with and without EGFR mutations treated with gefitinib were 25.1 and 14.0 months, respectively. Patients with EGFR mutations had approximately 2-fold survival advantage; however, the difference was not significant. Conclusions: We show that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=19944433797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944433797&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1167

EP - 1173

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -